Skip to main content
      Where do patients find informations about their RMD?

      Study of 705pts

      -80% search engines via smartphone 80.3%
      Differen

      Aurelie Najm AurelieRheumo

      1 week 6 days ago
      Where do patients find informations about their RMD? Study of 705pts -80% search engines via smartphone 80.3% Different pattern within 2 yrs of diagnosis vs. later stage: -more frequent 19% vs 8% Most users find online content -understandable 80% -apply it in daily life 68% https://t.co/9IMvpt2ffr
      More biomarkers predictive of conversion to clinical RA in at-risk pts

      Serum PAD4 & PAD 4 levels measured in CCP+ a

      Aurelie Najm AurelieRheumo

      1 week 6 days ago
      More biomarkers predictive of conversion to clinical RA in at-risk pts Serum PAD4 & PAD 4 levels measured in CCP+ at-risk individuals -PAD4 (not PAD2) increased in RA Converters vs. non converters and HC -PAD4 levels Pre-RA = RA Within high CCP+ at risk individuals, higher https://t.co/LU5zUzui1G
      Trying to reach RA, PsA patients on social media, to participate in studies?

      Simple, informational messages work for re

      David Liew drdavidliew

      1 week 6 days ago
      Trying to reach RA, PsA patients on social media, to participate in studies? Simple, informational messages work for recruitment Message framing affects engagement but not recruitment The more we understand, the better we can reach the right people #ACR25 ABST0187 @RheumNow https://t.co/JoAthXhXvi
      A simple flow cytometry analysis of peripheral blood monocytes to predicts progression to clinical RA or PsA in at-risk

      Aurelie Najm AurelieRheumo

      1 week 6 days ago
      A simple flow cytometry analysis of peripheral blood monocytes to predicts progression to clinical RA or PsA in at-risk patients? Too good to be true! 284 RA 56 PsA 57 HC -HLA-DR higher in PsA -CD11c lower in RA But no clear difference between Converters and non Converters https://t.co/f3Sett4eXd
      Rheumatologists love AI scribes in clinic.

      The way we interact is potentially well suited, and accuracy and synthesis q

      David Liew drdavidliew

      1 week 6 days ago
      Rheumatologists love AI scribes in clinic. The way we interact is potentially well suited, and accuracy and synthesis quality is bound to improve. Is it inevitable that it will universally be standard practice for us soon? UCSF clinics #ACR25 @JYazdanyMD ABST0189 @RheumNow https://t.co/kOzfpLlvgD
      CMV is a worry with high-dose steroids, especially in certain settings.

      The risk is far from universal, though: in this

      David Liew drdavidliew

      1 week 6 days ago
      CMV is a worry with high-dose steroids, especially in certain settings. The risk is far from universal, though: in this Korean cohort treated with high dose pred, almost no-one without risk factors got it. Meds are rarely the only infection risk factor #ACR25 ABST203 @RheumNow https://t.co/zLYhLVKgYL
      #ACR25 Abstr#803 We need more data to justify biologics before conventional immunosuppressant in #SLE. Post-hoc analysis

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 6 days ago
      #ACR25 Abstr#803 We need more data to justify biologics before conventional immunosuppressant in #SLE. Post-hoc analysis of 5 Phase 3 RCTs = improved efficacy & GC reduction in BEL+No IS vs PBO+IS. Potential selection bias as control group might be doomed to fail @RheumNow https://t.co/kXmrOUbJzj
      #0793 In #SLE, abusive trauma was linked to 58% higher risk of medication non-adherence; resilience buffered this effect

      Mrinalini Dey DrMiniDey

      1 week 6 days ago
      #0793 In #SLE, abusive trauma was linked to 58% higher risk of medication non-adherence; resilience buffered this effect. Patients with trauma cited motivational, not access-related, barriers. Trauma-informed & resilience-focused care may improve adherence. @RheumNow #ACR25
      #0794 LLMs can accelerate qualitative lupus pregnancy research. Using AI to translate & analyze interviews from Port

      Mrinalini Dey DrMiniDey

      1 week 6 days ago
      #0794 LLMs can accelerate qualitative lupus pregnancy research. Using AI to translate & analyze interviews from Portuguese, GPT-4 achieved top accuracy & coherence vs human themes. LLMs may expand inclusion & equity in rheum research. @RheumNow #ACR25 https://t.co/TAxg6Qyk0L
      Real-world Indian cohort of 290 axSpA patients, generic tofacitinib achieved low/inactive disease in 89% after 25 months

      Antoni Chan MD (Prof) synovialjoints

      1 week 6 days ago
      Real-world Indian cohort of 290 axSpA patients, generic tofacitinib achieved low/inactive disease in 89% after 25 months. Most adverse events were mild (e.g., transaminitis 14.5%) and manageable. No serious infections or MACE reported. A cost-effective alternative to bDMARDs in https://t.co/JBHfNq7kYt
      New Gout Therapies Show Promise in Phase III Trials
      • ACR Press Release
      At ACR Convergence 2025, the American College of Rheumatology’s annual meeting, researchers presented pivotal Phase III studies highlighting novel therapeutic options for patients with gout, particularly those with limited treatment choices or uncontrolled disease. The findings underscore continuing progress in addressing a significant unmet need for safer, more effective therapies in this common and often debilitating condition.
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All

      Dr. John Cush RheumNow

      1 week 6 days ago
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
      At ACR Convergence 2025, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. Studies presented at the meeting highlighted issues ranging from kidney transplant outcomes in lupus to medication disparities in rheumatoid arthritis and demographic patterns in systemic sclerosis and axial spondyloarthritis.
      Upadacitinib in GCA doesn't just affect IL-6, it alters IFNg, known to be important in vascular change in GCA.

      If UPA i

      David Liew drdavidliew

      1 week 6 days ago
      Upadacitinib in GCA doesn't just affect IL-6, it alters IFNg, known to be important in vascular change in GCA. If UPA in GCA has some cardiovascular concerns extrapolated from RA, it also has some plausible cardiovascular benefits too that TCZ may not #ACR25 ABST0751 @RheumNow https://t.co/rMetLPP9z6
      ×